Daniel Blessing active positions
Companies | Position | Start | End |
---|---|---|---|
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - | - |
Founder | - | - |
Career history of Daniel Blessing
Statistics
International
Switzerland | 2 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
HAYA Therapeutics SA
HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Daniel Blessing
- Experience